GENNEX LABORATORIES
|
|
BOM : 531739     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : NA |
May 27,2022 |
Price(EOD): ₹ 6.82
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 86.27 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GENNEX LABORATORIES | -3.1% | -13.2% | 6.1% |
SUN PHARMACEUTICAL INDUSTRIES | -1.9% | -0.2% | 29.4% |
DIVIS LABORATORIES | -9.8% | -22.2% | -15.5% |
DR REDDYS LABORATORIES | 2.8% | 7.7% | -17.4% |
CIPLA | -0.4% | -1.1% | 3.1% |
GLAND PHARMA | -2.5% | -7.7% | -13% |
PIRAMAL ENTERPRISES | -12.8% | -23.8% | 9.1% |
CADILA HEALTHCARE | 3.1% | 8.4% | -40.1% |
TORRENT PHARMACEUTICALS | 12.4% | 8.5% | 6.5% |
FUNDAMENTAL ANALYSIS OF GENNEX LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GENNEX LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
21.31
P/E Calculated based on EPS of 0.32
[ Mar2021 - Consolidated Results ] 2.17
P/B Calculated based on Book Value of 3.14
[ Mar2021 - Consolidated Results ] 1.51
P/S Calculated based on Revenues of 56.962 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
81% 50% 48% |
SHARE PRICE MOMENTUM OF GENNEX LABORATORIES
GENNEX LABORATORIES vs SENSEX
DEBT OF GENNEX LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.18 0.14 0.13 0.15 |
0.19 0.14 0.13 0.15 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GENNEX LABORATORIES
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GENNEX LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
16.73% -31.38% -33.44% -28.6% |
10.25% -20.02% -17.95% -8.79% |
QtrlyTrend |
-4 | |
Latest Qtr: Dec2021 | ||
Quarterly Result Analysis → |
GENNEX LABORATORIES related INDICES
You may also like the below Video Courses
FAQ about GENNEX LABORATORIES
Is GENNEX LABORATORIES good for long term investment?
As on May 27,2022, the Fundamentals of GENNEX LABORATORIES look Poor and hence it may not be good for long term investment ! See Financial Performance of GENNEX LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GENNEX LABORATORIES UnderValued or OverValued?
As on May 27,2022, GENNEX LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GENNEX LABORATORIES ?
As on May 27,2022, the Intrinsic Value of GENNEX LABORATORIES is Rs. 4.56 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3.76
Fair Value [Median EV / Sales Model] : Rs. 4.56
Fair Value [Median Price / Sales Model] : Rs. 4.60
Median Fair Value of GENNEX LABORATORIES : Rs. 4.56
Is GENNEX LABORATORIES trading at a Premium or Discount?
As on May 27,2022, GENNEX LABORATORIES is trading at a Premium of 50% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
